NIH won't cut price of taxpayer-funded prostate cancer drug

The federal government has declined a petition to lower the price of a prostate cancer drug developed with taxpayer money.

The public interest group Knowledge Ecology International petitioned the National Institutes of Health in January to reduce the $129,000-a year list price of Xtandi (ex-TAN'-dee), made by the Japanese drugmaker Astellas Pharma.

NIH won't cut price of taxpayer-funded prostate cancer drug